JP2024526939A5 - - Google Patents

Info

Publication number
JP2024526939A5
JP2024526939A5 JP2024503840A JP2024503840A JP2024526939A5 JP 2024526939 A5 JP2024526939 A5 JP 2024526939A5 JP 2024503840 A JP2024503840 A JP 2024503840A JP 2024503840 A JP2024503840 A JP 2024503840A JP 2024526939 A5 JP2024526939 A5 JP 2024526939A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
ester
progression
rate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024503840A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024526939A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/038072 external-priority patent/WO2023004151A1/en
Publication of JP2024526939A publication Critical patent/JP2024526939A/ja
Publication of JP2024526939A5 publication Critical patent/JP2024526939A5/ja
Pending legal-status Critical Current

Links

JP2024503840A 2021-07-22 2022-07-22 酸化的網膜疾患の進行を抑制する方法 Pending JP2024526939A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163224679P 2021-07-22 2021-07-22
US202163224690P 2021-07-22 2021-07-22
US202163224674P 2021-07-22 2021-07-22
US63/224,690 2021-07-22
US63/224,674 2021-07-22
US63/224,679 2021-07-22
PCT/US2022/038072 WO2023004151A1 (en) 2021-07-22 2022-07-22 Methods for inhibiting the progression of oxidative retinal diseases

Publications (2)

Publication Number Publication Date
JP2024526939A JP2024526939A (ja) 2024-07-19
JP2024526939A5 true JP2024526939A5 (cg-RX-API-DMAC7.html) 2024-07-29

Family

ID=84979648

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024503840A Pending JP2024526939A (ja) 2021-07-22 2022-07-22 酸化的網膜疾患の進行を抑制する方法

Country Status (8)

Country Link
US (1) US20250099415A1 (cg-RX-API-DMAC7.html)
EP (1) EP4373479A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024526939A (cg-RX-API-DMAC7.html)
KR (1) KR20240036651A (cg-RX-API-DMAC7.html)
AU (1) AU2022313207A1 (cg-RX-API-DMAC7.html)
CA (2) CA3227139A1 (cg-RX-API-DMAC7.html)
IL (1) IL310210A (cg-RX-API-DMAC7.html)
WO (1) WO2023004151A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240091187A1 (en) * 2022-09-02 2024-03-21 Biojiva Llc Pharmaceutical compositions of d10-docosahexaenoic acid or esters thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060270739A1 (en) * 2005-04-28 2006-11-30 Trustees Of Tufts College Synergistic effects of docosahexaenoic acid (DHA) and carotenoid absorption on macular pigmentation
US20100303887A1 (en) * 2007-07-30 2010-12-02 Bazan Nicolas G DHA and PEDF, a Therapeutic Composition for Nerve and Retinal Pigment Epithelial Cells
EP2219638A2 (en) * 2007-10-29 2010-08-25 Board of Supervisors of Louisiana State University and Agricultural and Mechanical College Lipoxin a4 protection for retinal cells
US10058522B2 (en) * 2011-04-26 2018-08-28 Retrotope, Inc. Oxidative retinal diseases
WO2017091279A1 (en) * 2015-11-23 2017-06-01 Retrotope, Inc. Site-specific isotopic labeling of 1, 4-diene systems
WO2020102596A1 (en) * 2018-11-15 2020-05-22 Retrotope, Inc. Deuterated compounds, compositions, and uses

Similar Documents

Publication Publication Date Title
EP3558458B1 (en) Glyceryl 3-hydroxybutyrates for migraine symptom management
JP4151853B2 (ja) エイコサペンタエン酸および/またはステアリドン酸を含む治療用薬剤
AU2014236004B2 (en) Compositions and methods for producing elevated and sustained ketosis
JP4596734B2 (ja) スタチン副作用の処置
KR20040004652A (ko) 조효소 q 및 에이코사펜타에노산(epa)
JPH06157303A (ja) 脂肪酸治療
CN1638753A (zh) 脂肪酸治疗效果的强化
JP2025510369A5 (cg-RX-API-DMAC7.html)
JP2001510799A (ja) 必須脂肪酸および生物活性ジスルフィドを含む治療用および食餌療法用組成物
JPH0714873B2 (ja) 局所性製薬組成物
NZ577731A (en) Compositions and methods for treatment of multiple sclerosis
JP2022521233A5 (cg-RX-API-DMAC7.html)
RU2005107416A (ru) Эйкозапентаеновая кислота (эпк) для лечения нервно-психической анорексии (на) и булимии
JP2025031720A5 (cg-RX-API-DMAC7.html)
US6288026B1 (en) Process and composition for treating diseases with an oil-in-water emulsion
US8299121B2 (en) Softgel of NLKJ for treating prostate diseases
CA2364606C (en) Oil-in-water emulsion for the use as medicament or for producing a medicament
JPH0399011A (ja) 医薬組成物
McCarty High-chromium yeast for acne?
JPS5998018A (ja) 老化治療剤
JP2024526939A (ja) 酸化的網膜疾患の進行を抑制する方法
JP5952556B2 (ja) 褥瘡治療剤
JP5710150B2 (ja) 潜伏性感染疾患の再発抑制剤
CA2504280A1 (en) Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease
ES2425045T3 (es) Acetil-L-carnitina para la prevención de la neuropatía diabética periférica dolorosa